In 260 adults with AChR antibody-positive generalised myasthenia gravis, weekly subcutaneous gefurulimab improved MG-ADL score at 26 weeks vs placebo (−4.2 vs −2.6; difference −1.6, P<.001); QMG also improved; adverse events were similar.
RCTn = 260
Gwathmey et al. Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial